ReviewFrontiers in human neuroscience2026
EEG alpha reactivity in cognitive aging and dementia: clinical implications and cholinergic mechanisms.
Review in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alpha Reactivity Dynamics Reveal Multi-System Variability Without Global Alpha Slowing in Fragile X Syndrome.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha reactivity-the attenuation of the alpha rhythms upon eye-opening-is a well-known phenomenon in electroencephalography (EEG). Altered alpha reactivity has increasingly been recognized as a potential biomarker for cognitive aging and various types of dementia. This mini-review synthesizes the existing literature on EEG alpha reactivity in older adults, highlighting its clinical implications and neurobiological underpinnings. Methodological issues in quantifying alpha reactivity are first addressed, including the choice of reactivity index, frequency bands, and spatial analysis methods. The review then summarizes evidence that alpha reactivity declines with healthy aging and is further reduced in dementia, especially Alzheimer's disease (AD) and Lewy body dementia (LBD). Importantly, distinct patterns of reduced alpha reactivity may aid in differential diagnosis. It has been reported that AD is often characterized by reduced alpha rhythm during eyes-closed rest, whereas LBD typically shows impaired alpha attenuation upon eye-opening. Neuroimaging and pharmacological studies suggest that alpha reactivity reflects cholinergic system integrity, particularly involving the nucleus basalis of Meynert and its projections to the visual cortex. In conclusion, EEG alpha reactivity is a promising, non-invasive biomarker of cognitive health and dementia subtypes. However, larger, harmonized, multimodal and longitudinal studies are needed to establish its diagnostic value and clarify its neurobiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.